• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Wave Life Sciences Ltd.

    5/6/26 11:40:40 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $WVE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    WAVE LIFE SCIENCES LTD

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)




    Y95308105

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    Y95308105


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    5,189,539.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,192,761.43
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,192,761.43
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.8 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP Number(s):
    Y95308105


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    5,192,761.43
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,192,761.43
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    WAVE LIFE SCIENCES LTD
    (b)Address of issuer's principal executive offices:

    7 STRAITS VIEW, #12-00,MARINA ONE EAST TOWER,SINGAPORE,U0,018936
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    Y95308105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    5192761.43
    (b)Percent of class:

    2.8  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    5192761.43

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of WAVE LIFE SCIENCES LTD. No one other person's interest in the COMMON STOCK of WAVE LIFE SCIENCES LTD is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Richard Bourgelas
    Name/Title:Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:05/05/2026
     
    Abigail P. Johnson
     
    Signature:Richard Bourgelas
    Name/Title:Duly authorized under Power of Attorney effective as of April 13, 2026, by and on behalf of Abigail P. Johnson*
    Date:05/05/2026

    Comments accompanying signature:  *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on April 29,2026, accession number: 0000315066-26-000738.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $WVE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WVE

    DatePrice TargetRatingAnalyst
    4/29/2026$15.00Buy
    Truist
    2/5/2026$38.00Buy
    BofA Securities
    12/12/2025$20.00 → $33.00Outperform
    Wedbush
    12/9/2025$27.00Sector Perform → Outperform
    RBC Capital Mkts
    10/20/2025$18.00Overweight
    Wells Fargo
    8/4/2025$19.00Buy
    Canaccord Genuity
    7/28/2025$24.00Outperform
    Oppenheimer
    7/16/2025$16.00Buy
    Citigroup
    More analyst ratings

    $WVE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eco Wave Power Featured for Second Time in NVIDIA Founder and CEO Jensen Huang's GTC Keynote, as Company Advances Taiwan Wave Energy Project

    TAIPEI, Taiwan, June 2, 2026 /PRNewswire/ -- Eco Wave Power Global AB (publ) (NASDAQ:WAVE), a leading onshore wave energy technology company, today announced that its technology was featured for the second time in an NVIDIA GTC keynote presentation, this time during NVIDIA Founder and CEO Jensen Huang's GTC Taipei 2026 keynote, highlighting the growing role of digital twins and simulation technologies in the optimization of real-world infrastructure. The latest appearance follows Eco Wave Power's inclusion in NVIDIA's GTC San Jose keynote presentation in March 2026, marking the

    6/2/26 8:30:00 AM ET
    $WAVE
    $WVE
    Electric Utilities: Central
    Utilities
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave's management team are scheduled to participate in two upcoming investor conferences in June. 2026 Jefferies Global Healthcare ConferenceDate: Wednesday, June 3, 2026 Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:30 a.m. ET Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Monday, June 8, 2026 Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:00 a.m

    6/1/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1

    The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.DURHAM, N.C., May 19, 2026 /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Wave Life Sciences as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.

    5/19/26 9:49:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Wright Christopher I

    3 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    4/17/26 9:00:05 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Ingelsson Erik

    3 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    4/17/26 9:00:03 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Ra Capital Management, L.P.

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    3/30/26 8:30:55 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    SEC Filings

    View All

    Wave Life Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

    8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

    5/18/26 4:51:59 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Wave Life Sciences Ltd.

    SCHEDULE 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    5/13/26 9:21:39 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Wave Life Sciences Ltd.

    DEF 14A - Wave Life Sciences Ltd. (0001631574) (Filer)

    5/7/26 4:01:18 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gsk Plc bought $27,930,000 worth of Ordinary Shares (1,470,000 units at $19.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    12/15/25 4:32:10 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $6,688 worth of Ordinary Shares (1,000 units at $6.69) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    11/14/25 6:14:02 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gsk Plc bought $22,335,440 worth of Ordinary Shares (2,791,930 units at $8.00) (SEC Form 4)

    4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

    10/1/24 5:54:39 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist resumed coverage on Wave Life Sciences with a new price target

    Truist resumed coverage of Wave Life Sciences with a rating of Buy and set a new price target of $15.00

    4/29/26 8:08:07 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Wave Life Sciences with a new price target

    BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00

    2/5/26 9:31:24 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush reiterated coverage on Wave Life Sciences with a new price target

    Wedbush reiterated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $33.00 from $20.00 previously

    12/12/25 8:29:31 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Financials

    Live finance-specific insights

    View All

    Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

    Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing  On track for feedback from FDA on potential accelerated approval pathway mid-2026 WVE-006 generated wild-type M-AAT comprising 64% of total AAT and reduced harmful Z-AAT by 71%, with 11.9 µM total AAT in the 200 mg biweekly cohort; effects were consistent with 400 mg monthly dosing regimen, with 13.6 µM total AAT; editing was sustained at least three months following last dose Restored dynamic AAT production with two new observations of elevated AAT during acute phase responses

    5/18/26 4:30:00 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

    With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the trial remains on track to initiate in 2Q 2026 Combination and maintenance trials of WVE-007 on track to initiate in 2026 Data from RestorAATion-2 trial of WVE-006 (GalNAc-RNA editing) in AATD (including 400 mg monthly dose and 600 mg single dose cohorts) to be presented at an investor webcast during the ATS International Conference in May 2026 Regulatory feedback on accelerated approval pathway for WVE-006 continues to be expected mid-2026 CTA submission for WVE-008 (GalNAc-RNA editing for PNPLA

    4/28/26 7:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026

    CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, April 28, 2026, to review the company's first quarter 2026 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call a

    4/22/26 8:30:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $WVE
    Leadership Updates

    Live Leadership Updates

    View All

    Wave Life Sciences Announces Appointment of Dr. Christopher Wright as Chief Medical Officer

    CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Christopher Wright, MD, PhD, as Chief Medical Officer. Dr. Wright will join Wave's executive team and lead global development, including medical, clinical and regulatory functions, to bring the company's RNA medicines to countless individuals who urgently need them. "Dr. Wright joins us with extensive global development leadership experience spanning both early and late-stage clinical development, including an impressive track-record of success

    5/28/25 8:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer

    CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

    5/9/24 7:00:00 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Athira Pharma Announces Appointment of Dr. Michael A. Panzara to its Board of Directors

    BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development

    3/21/22 7:05:00 AM ET
    $ATHA
    $WVE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $WVE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 4:30:35 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Wave Life Sciences Ltd.

    SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    11/12/24 9:34:18 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Wave Life Sciences Ltd.

    SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)

    10/1/24 5:47:15 PM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care